Since our methylation data in glioma patients suggested that TAGLN2 expression might be silenced in IDH1/2 mutant LGGs by promoter hypermethylation, we confirmed these results in vitro by treating IDH1 mutant U87 MG cells with 5-aza-2′-deoxycytidine (5-AZA), an inhibitor of DNA methyltransferase that results in DNA demethylation [32]. This evidence concerns the gene IDH1 and central nervous system cancer.